AC Immune (ACIU) announced the appointment of Prof. Catherine Mummery, a deeply experienced neurologist and expert in dementia clinical trials, as Chairwoman of its Clinical Advisory Board, CAB. Prof. Mummery leads the cognitive disorders service at the UK’s National Hospital for Neurology and Neurosurgery, where she has practiced as a consultant neurologist since 2004.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune’s ACI-24.060 Study: A Potential Game-Changer in Alzheimer’s Treatment
- AC Immune’s Innovative PET Tracer Study: A Potential Game-Changer for Neurodegenerative Diagnostics
- AC Immune’s Innovative PET Radioligand Study: A Potential Game-Changer in Neurodegenerative Diagnostics
- AC Immune SA: Pioneering Innovations in Neurodegenerative Disease Treatment and Diagnostics
- AC Immune announces publication of preclinical data on ACI-19626